Erratum: Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial (The Lancet (2015) 385(9973) (1087–1097) (S0140673614617931) (10.1016/S0140-6736(14)61793-1));Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): A randomised, open-label phase 2 trial

The Lancet

Volumn 385, Issue 9973, 2015, Pages 1087-1097

  Sulkowski, Mark ^a   Hezode, Christophe ^b   Gerstoft, Jan ^c   Vierling, John M ^d   Mallolas, Josep ^e   Pol, Stanislas ^f   Kugelmas, Marcelo ^g   Murillo, Abel ^h   Weis, Nina ⁱ   Nahass, Ronald ^j   Shibolet, Oren ^k   Serfaty, Lawrence ^l   Bourliere, Marc ^m   Dejesus, Edwin ⁿ   Zuckerman, Eli ^o   Dutko, Frank ^p   Shaughnessy, Melissa ^p   Hwang, Peggy ^p   Howe, Anita Y M ^p   Wahl, Janice ^p   Robertson, Michael ^p   Barr, Eliav ^p   Haber, Barbara ^p   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRI MONDOR HOSPITAL   (France)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g South Denver Gastroenterology   (United States)

^h Advanced Medical and Pain Management Research Clinic   (United States)

ⁱ Copenhagen University Hospital ^*  (Denmark)

^j ID Care   (United States)

^k TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^l HÔPITAL SAINT ANTOINE   (France)

^m HÔPITAL SAINT JOSEPH   (France)

ⁿ ORLANDO IMMUNOLOGY CENTER   (United States)

^o CARMEL MEDICAL CENTER   (Israel)

^p MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ELBASVIR; GRAZOPREVIR; NONSTRUCTURAL PROTEIN 5A; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; MK-5172; QUINOXALINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; BENZOFURANS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; QUINOXALINES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84925423399     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60601-8     Document Type: Erratum

References (33)

1. K Mohd Hanafiah, J Groeger, AD Flaxman, ST Wiersma Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to hepatitis C virus seroprevalence Hepatology 57 2013 1333 1342
2. T Schoen-Angerer, J Cohn, T Swan, P Piot UNITAID can address HCV/HIV coinfection Lancet 381 2013 628
3. E Gower, C Estes, S Hindman, K Razavi-Shearer, H Razavi Global epidemiology and genotype distribution of the hepatitis C virus infection J Hepatol 2014 10.1016/j.jhep.2014.07.027 published online July 30.
4. van der Helm, R Geskus, C Sabin et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997 Gastroenterology 144 2013 751 760
5. AJ van der Meer, BJ Veldt, JJ Feld et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
6. JR Kramer, F Kanwal, P Richardson, M Mei, HB El Serag Gaps in the achievement of effectiveness of HCV treatment in national VA practice J Hepatol 56 2012 320 325
7. CE McGowan, A Monis, BR Bacon et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care Hepatology 57 2013 1325 1332
8. EG Hulskotte, HP Feng, F Xuan et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir Clin Infect Dis 56 2013 718 726
9. FJ Torriani, M Rodriguez-Torres, JK Rockstroh et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
10. European Association for the Study of the Liver Recommendations on treatment of hepatitis C 2014 J Hepatol 61 2014 373 395
11. American Association for the Study of Liver Diseases/Infectious Diseases Society of America/International Antiviral Society-USA Recommendations for testing, managing, and treating hepatitis C http://www.hcvguidelines.org 2014 (accessed Sept 5, 2014).
12. V Summa, SW Ludmerer, JA McCauley et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob Agents Chemother 56 2012 4161 4167
13. CA Coburn, PT Meinke, W Chang et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity ChemMedChem 8 2013 1930 1940
14. F Lahser, R Liu, K Bystol et al. A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in vitro in HCV replicons Hepatology 56 suppl S1 2012 236A
15. O Miettinen, M Nurminen Comparative analysis of two rates Stat Med 4 1985 213 226
16. M Manns, P Marcellin, F Poordad et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426
17. IM Jacobson, GJ Dore, GR Foster et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2014 403 413
18. RT Chung, J Andersen, P Volberding et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459
19. F Carrat, F Bani-Sadr, S Pol et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial JAMA 292 2004 2839 2848
20. M Rodriguez-Torres, J Slim, L Bhatti et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial HIV Clin Trials 13 2012 142 152
21. SJ Hadziyannis, H Sette Jr, TR Morgan et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
22. R Bartenschlager, V Lohmann, F Penin The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection Nat Rev Microbiol 11 2013 482 496
23. MS Sulkowski, S Naggie, J Lalezari et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection JAMA 312 2014 353 361
24. JJ Feld, KV Kowdley, E Coakley et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
25. KV Kowdley, SC Gordon, KR Reddy et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
26. P Ferenci, D Bernstein, J Lalezari et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV N Engl J Med 370 2014 1983 1992
27. KV Kowdley, E Lawitz, F Poordad et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1 N Engl J Med 370 2014 222 232
28. AS Lok, DF Gardiner, C Hezode et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders J Hepatol 60 2014 490 499
29. JM Molina, C Orkin, DM Iser et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes 1, 2, 3 and 4 infection in patients coinfected with HIV (PHOTON-2). 20th International AIDS Conference; Melbourne, VIC, Australia; July 20-25, 2014. Abstr MOAB0105LB http://pag.aids2014.org/abstracts.aspx?aid=11072 (accessed Sept 5, 2014).
30. M Sulkowski, JJ Eron, DJ Wyles et al. TURQUOISE-I: Safety and efficacy of ABT-450/r/ombitasvir, dasabuvir and ribavirin in patients coinfected with hepatitis C and HIV-1. 20th International AIDS Conference; Melbourne, VIC, Australia; July 20-25, 2014. Abstr MOAB0104LB http://pag.aids2014.org/abstracts.aspx?aid=11024 (accessed Sept 5, 2014).
31. E Lawitz, E Gane, B Pearlman et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial Lancet 2014 published online Nov 11. http://dx.doi.org/10.1016/S0140-6736(14)61795-5
32. W Yeh, I Fraser, L Caro et al. No meaningful PK interaction between HCV protease inhibitor MK-5172 and tenofovir or raltegravir Top Antivir Med 22 2014 238 39 (abstr)
33. M Sulkowski, J Mallolas, M Bourliere et al. On-treatment viral response to MK-5172/MK-8742 plus RBV for 12 weeks in HCV/HIV-coinfected patients Top Antivir Med 22 2014 324 25 (abstr)